Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 2,908 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Oxidative Stress, Healthy Aging, Skin Health
Interventions: Solarplast; Dietary Supplement
Lead sponsor: Deerland Enzymes; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Healthy
Interventions: PF-06669571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Heart Failure
Interventions: Ivabradine, Placebo; Drug
Lead sponsor: Phillip Levy; Other
Eligibility: 19 Years to 89 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Alopecia Areata
Interventions: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more

Conditions: Fragile X Syndrome
Interventions: STX209, Placebo; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 6 Years to 40 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more

Conditions: Essential Thrombocythemia
Interventions: Ropeginterferon alfa-2b, Anagrelide; Biological · Drug
Lead sponsor: PharmaEssentia; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 4
States / cities: Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Muscle Soreness
Interventions: Riboflavin, Placebo; Drug
Lead sponsor: Steven Moore; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Low Back Pain
Interventions: Orphenadrine, Methocarbamol, Naproxen, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hepatitis C, Chronic
Interventions: Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 85
States / cities: Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: Tourettes Syndrome, Tic
Interventions: N-Acetylcysteine (NAC), Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions: BMN 255, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more

Conditions: Breast Neoplasms
Interventions: Exemestane, Celecoxib + Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Eosinophilic Esophagitis
Interventions: Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule; Diagnostic Test · Other · Drug
Lead sponsor: Claire Daniels; Federal
Eligibility: 6 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: LCZ696, Valsartan, AHU377, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more

Conditions: Squamous Non-Small Cell Lung Cancer
Interventions: Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 38
States / cities: Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Maitland, Florida

Conditions: Attention, Memory, Alertness
Interventions: oréVida™, Placebo; Dietary Supplement
Lead sponsor: dsm-firmenich Switzerland AG; Industry
Eligibility: 35 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Multiple System Atrophy
Interventions: TEV-56286, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 26
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Interventions: Estradiol, Placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 100
States / cities: Huntsville, Alabama • Montgomery, Alabama • Mesa, Arizona + 85 more

Conditions: Cocaine Dependence
Interventions: D-serine, Cognitive Behavioral Therapy, Placebo; Drug · Behavioral
Lead sponsor: Theresa Winhusen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions: Famotidine, Celecoxib, Placebo; Drug
Lead sponsor: Leidos Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more

Conditions: Ototoxicity
Interventions: Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Heart Failure
Interventions: GSK2798745, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Search by objective public record fields.

Efficacy of Solarplast for Health and Oxidative Stress

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes

Orphenadrine and Methocarbamol for LBP

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

N-acetylcysteine (NAC) for Children With Tourette Syndrome

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

D-Serine for Cocaine Dependence Pilot

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure